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Peripheral Signals Conveying Metabolic
Information to the Brain: Short-Term and
Long-Term Regulation of Food Intake and
Energy Homeostasis
PETER J. HAVEL1
Department of Nutrition, University of California, Davis, California 95616
Numerous peripheral signals contribute to the regulation of
food intake and energy homeostasis. Mechano- and chemore-
ceptors signaling the presence and energy density of food in
the gastrointestinal (GI) tract contribute to satiety in the imme-
diate postprandial period. Changes in circulating glucose con-
centrations appear to elicit meal initiation and termination by
regulating activity of specific hypothalamic neurons that re-
spond to glucose. Other nutrients (e.g., amino acids and fatty
acids) and GI peptide hormones, most notably cholecystokinin,
are also involved in short-term regulation of food intake. How-
ever, the energy density of food and short-term hormonal sig-
nals by themselves are insufficient to produce sustained
changes in energy balance and body adiposity. Rather, these
signals interact with long-term regulators (i.e., insulin, leptin,
and possibly the orexigenic gastric peptide, ghrelin) to maintain
energy homeostasis. Insulin and leptin are transported into the
brain where they modulate expression of hypothalamic neuro-
peptides known to regulate feeding behavior and body weight.
Circulating insulin and leptin concentrations are proportional to
body fat content; however, their secretion and circulating levels
are also influenced by recent energy intake and dietary macro-
nutrient content. Insulin and leptin concentrations decrease
during fasting and energy-restricted diets, independent of body
fat changes, ensuring that feeding is triggered before body en-
ergy stores become depleted. Dietary fat and fructose do not
stimulate insulin secretion and leptin production. Therefore, at-
tenuated production of insulin and leptin could lead to in-
creased energy intake and contribute to weight gain and obe-
sity during long-term consumption of diets high in fat and/or
fructose. Transcription of the leptin gene and leptin secretion
are regulated by insulin-mediated increases of glucose utiliza-
tion and appear to require aerobic metabolism of glucose be-
yond pyruvate. Other adipocyte-derived hormones and proteins
that regulate adipocyte metabolism, including acylation stimu-
lating protein, adiponectin, diacylglycerol acyltransferase,
and perilipin, are likely to have significant roles in energy
homeostasis. [Exp Biol Med Vol. 226(11):963–977, 2001]
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There is considerable evidence that body weight andbody fat content are well regulated. In adult animalsand humans, body weight tends to remain within a
relatively narrow range, despite large day-to-day fluctua-
tions in the amount of food consumed. Although major
changes of body adiposity can be induced in humans and
animals by restricting energy intake or by overfeeding, body
weight and adiposity return very close to baseline levels
when ad libitum feeding is resumed (reviewed in Refs. 1–3).
Investigations of the regulation of food intake in surgically
joined parabiotic animals in which circulating substances
can move between animals supported the hypothesis that a
humorally transported factor or factors is involved in regu-
lating feeding behavior. For example, when one member of
a pair of parabiotic rodents is overfed via stomach tube, the
other member of the pair reduces its voluntary food intake
(4, 5). The potential humoral signals identified by such ex-
periments were postulated to be either nutrients, nutrient
metabolites, or hormones.
Although there are many peripheral signals that can
contribute to feeding behavior and body weight regulation,
it is important to recognize that short-term and long-term
food intake and energy balance are regulated through dis-
tinct, but interacting, mechanisms. In this context, some
signals (e.g., nutrients and gastrointestinal [GI] hormones)
act primarily as determinants of satiety to limit the size of
individual meals (see Fig. 1 for overview). These short-term
signals have a markedly different function than the long-
term regulators of energy homeostasis that are activated in
proportion to both body adipose stores and to the amount of
energy consumed over a more prolonged period of time.
Insulin and leptin are two such long-term signals. These
hormones regulate food intake and energy expenditure to
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ensure that energy homeostasis is maintained and that body
weight and adiposity remain relatively constant (see Fig. 2
for overview). In contrast, short-term signals are not pri-
mary determinants of body adiposity since they can be over-
ridden by long-term regulatory signals. Nonetheless, the
short-term and long-term mechanisms need to function in
concert to integrate energy intake and energy expenditure to
ensure that energy balance is maintained.
Nutrients
Glucose. A glucostatic hypothesis for the regulation
of feeding behavior was proposed by Mayer nearly 50 years
ago (6). This hypothesis has recently been revisited and
reviewed (7). Hypoglycemia or inhibition of glucose me-
tabolism with the glucose analog 2 deoxy-D-glucose in-
creases food intake in animals (8) and increases hunger
sensations and food intake in humans (9). This effect of
hypoglycemia or 2-deoxy-D-glucose has been termed glu-
coprivic feeding. In 1969, Oomura and colleagues (10) re-
ported that populations of neurons in the ventromedial and
in the lateral hypothalamus increase their firing rates in
response to the application of glucose. These glucose-
sensitive/responsive neurons are likely to be responsible for
the effects of glucoprivation to induce feeding. Other inves-
tigators have suggested that glucoprivic feeding may be
regulated by receptors in the hindbrain (11) or in the liver
(12). However, destruction of specific hypothalamic neu-
rons by gold-thioglucose administration in mice results in a
classic hypothalamic obesity syndrome associated with hy-
perphagia, and blocks the effect of glucose to suppress food
intake (13), suggesting a key role for hypothalamic glucose-
responsive neurons in regulating feeding behavior. Interest-
ingly, there appear to be similarities in the metabolic events
that activate glucose-responsive neurons in the hypothala-
mus in those that are involved in glucose-induced insulin
secretion in  cells (14), and in the mechanisms by which
insulin-mediated glucose metabolism stimulates leptin pro-
duction by adipocytes (see below).
Although it is clear that an acute marked lowering of
circulating glucose concentrations will trigger sensations of
hunger, and that infusing glucose decreases food intake in
baboons (15) and increases sensations of satiety in humans
(16), the role of more subtle physiological changes of glu-
cose in the regulation of feeding behavior has been difficult
to characterize. Some studies have suggested that changes
of substrate utilization/oxidation are involved in glucose-
induced satiety (17). In fact, Mayer (6) proposed that arte-
riovenous glucose gradients, reflecting increased glucose
utilization, were more important than absolute blood glu-
cose concentrations. In these studies, smaller arteriovenous
differences were associated with increased hunger, whereas
larger arteriovenous differences were associated with
satiety.
In addition to actions that limit food intake, changes of
glucose or glucose utilization may also be involved in ini-
tiation of feeding. In a series of experiments, Campfield and
Smith (18) demonstrated that small (10–15 mg/dl) transient
decreases of blood glucose preceded spontaneous meal
feeding in rats, and that blocking these decreases of circu-
lating glucose prevented meal initiation. In contrast, admin-
Figure 1. Short-term signals regulating food intake. Signals from the
GI tract and the liver are involved in short-term regulation of feeding.
Afferent signals travel in vagal nerve fibers from stretch receptors,
and chemoreceptors activated by the presence of nutrients in the
stomach and proximal small intestine are involved in meal termina-
tion. Nutrients arriving via the portal vein may also trigger vagal
afferent signals from the liver. Glucose can modulate food intake by
acting on glucose-responsive neurons in the CNS. Ketones appear
to decrease appetite. In response to nutrient stimulation, the proxi-
mal intestine releases cholecystokinin (CCK), which reaches the
liver via the portal vein and the CNS via the systemic circulation;
CCK may act on CCK-A receptors at both sites to inhibit food intake.
Endocrine L cells in the terminal small intestine (ileum) release glu-
cagon-like peptide-1 (GLP-1), which inhibits feeding, most likely at a
hepatic site or by inhibiting gastric emptying. The short-term signals
by themselves do not produce sustained alterations in energy intake
and body adiposity.
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istration of another hexose, fructose, does not block initia-
tion of feeding (19). The declines of glucose are preceded
by a spike of plasma insulin concentrations, and meal feed-
ing can be induced by mimicking the naturally occurring
glucose declines by administering small amounts of insulin.
Small decreases of blood glucose have also been observed
prior to spontaneous meal consumption in human subjects,
suggesting that a similar mechanism may be operative in
primates (20). Thus, circulating glucose and changes of glu-
cose metabolism are clearly important in the regulation of
food intake; however, the glucostatic and glucodynamic
models of food intake regulation are not sufficient by them-
selves to explain the complex regulation of feeding behavior.
Protein (Amino Acids). There is some evidence in
favor of a role for dietary protein intake or increased circu-
lating amino acids in the regulation of food intake. A rela-
tionship between fluctuations in serum amino acids and ap-
petite in humans was originally suggested by Mellinkoff et
al. (21) in 1956 and was recently revisited (22). Dietary
protein does induce satiety in the short term (23), and con-
sumption of protein-deficient diets leads to increased appe-
tite for protein-containing foods (24). Although the mecha-
nisms underlying this phenomenon are not well understood,
administration of amino acids such as phenylalanine and
tryptophan that are precursors to monoamine neurotransmit-
ters suppresses food intake in humans (25). The ratio of
plasma tryptophan to other amino acids may influence brain
serotonin levels, which are known to have an inhibitory
influence on food intake (26). Furthermore, deficiencies of
certain amino acids in the diet of rats lead to rapid reduction
of food intake that is mediated via specific pathways in the
brain (27). Amino acids may influence food intake either via
direct actions within the CNS or via receptors located in the
liver or portal vein (28).
Fat (Triglycerides, Fatty Acids, and Apolipo-
proteins). The intravenous infusion of lipid substrates
such as Intralipid, along with heparin to release lipoprotein
lipase and hydrolyze triglyceride to fatty acids and glycerol,
decreases food intake in baboons (15). These data suggest
that an increase of circulating lipids, in the absence of GI
absorption, regulates feeding. However, it is unclear how
much concomitant increases of ketones, resulting from en-
hanced delivery of fatty acids to the liver, might contribute
to the effect of lipid infusion on food intake, since ketones
can be used as a metabolic substrate by the CNS and are
known to inhibit feeding (29). In addition to the inhibitory
effects of fat administration, reducing fatty acid utilization
with inhibitors of fat oxidation, mecaptoacetate or methyl
palmoxirate, stimulates food intake in animals, a phenom-
enon known as lipoprivic feeding (30). Like inhibition of
glucose metabolism, inhibition of lipid metabolism in-
creases expression of the orexigenic neuropeptide melanin-
concentrating hormone in the lateral hypothalamus. How-
ever, unlike glucoprivation, it does not increase expression
of neuropeptide Y (NPY) or agouti-related peptide in the
arcuate nucleus (31), both of which are orexigens. Friedman
(32) has proposed that the rate of fatty acid oxidation and its
effect on adenylate charge in the liver are involved in regu-
lating food intake.
Transport mechanisms (33) and enzymes for fat oxida-
tion (34) and fat synthesis (35) are also present in the brain,
and administration of inhibitors of fat synthesis produces a
centrally mediated inhibition of food intake in rodents (35,
36). Another lipid-related product potentially involved in
the regulation of food intake is the apolipoprotein, Apo
AIV. The production of Apo AIV in the intestine is stimu-
lated by fat absorption, and administration of Apo AIV
inhibits food intake (reviewed in Ref. 37). This apolipopro-
tein is also produced in the hypothalamus, and Apo AIV of
central origin may also have a role in food intake regulation
(38). Despite the potential for fat and fat metabolism to
inhibit food intake, there is abundant evidence that con-
sumption of diets high in energy from fat leads to increased
energy intake, weight gain, and obesity in animals and hu-
mans (39–42).
Metabolites. In addition to glucose, amino acids, and
fatty acids, a number of other metabolic products have ef-
fects on food intake. Lactate (43), pyruvate (43), and ke-
tones (29) inhibit feeding in animals. Postprandial circulat-
ing lactate concentrations are increased in proportion to the
carbohydrate content of meals (44), and could therefore
contribute to the short-term inhibition of food intake during
carbohydrate consumption. Increased circulating ketones
generated in response to moderate or short-term energy re-
striction do not appear to affect appetite or food intake,
since appetite increases dramatically at the same time ke-
tones are increasing. In contrast, the severe ketonemia that
occurs during prolonged energy restriction (i.e., starvation)
could inhibit hunger occurring under this extreme condition.
Similarly, the marked ketonemia accompanying consump-
tion of high fat, very low carbohydrate diets may contribute
to the decreased energy intake and weight loss that have
been reported to occur during consumption of some popular
weight loss diets (45).
Signals from the GI Tract
Mechano- and Chemoreceptors. GI chemorecep-
tors respond to the nutrient products of digestion (sugars,
fatty acids, amino acids, and peptides). In addition, entry of
food into the stomach and proximal small intestine activates
stretch and mechano-receptors. Signals from these GI re-
ceptors are transmitted via vagal afferent nerves to the hind-
brain where integration of this visceral input occurs. This
provides a pathway whereby the physical and chemical
properties of food can have a major role in short-term regu-
lation of food intake by limiting the size of a single meal.
These types of signals may also affect energy intake in a
subsequent meal (reviewed in Ref. 46). For example, con-
sumption of a large volume meal with a low nutrient/energy
density can decrease subsequent food intake over a limited
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period of time, usually 1 day. However, when the energy
density of food is decreased over a more prolonged period
of time by dilution with non-nutritive ingredients and the
macronutrient proportions of the diets remain the same,
more frequent but smaller meals are consumed such that
energy intake remains relatively constant (47, 48). Thus,
volume detection does not appear to have a major role in the
long-term regulation of energy balance and body adiposity
(reviewed in Ref. 48).
Hormones. Numerous GI hormones have been im-
plicated in food intake regulation. With the exception of one
of the more recently discovered GI hormones, ghrelin, these
peptides uniformly inhibit food intake (reviewed in Ref.
50). It is important to consider that many of these GI pep-
tides and their receptors are also present in regions of the
CNS involved in regulating feeding behavior. Most GI pep-
tides that inhibit feeding when administered peripherally
also do so, but at much lower doses, when administered
directly into the brain. Thus, it has often been unclear if the
primary target for these GI peptides is in the periphery, in
the CNS, or in both. It is likely that the peripheral and CNS
production and actions of GI peptides represent parallel
pathways in the modulation of feeding behavior.
CCK. There is a large body of data from studies in-
vestigating the role of CCK in food intake regulation (re-
viewed in Refs. 51 and 52). CCK is released from endocrine
cells localized in the mucosal layer of the proximal small
intestine. This release is primarily stimulated by dietary fat
and by amino acids and small peptides released during pro-
tein digestion. Administration of exogenous CCK was first
shown to decrease meal size in rats in 1973 (53) and sub-
sequently in nonhuman primates (54, 55) and in humans
(56, 57). CCK inhibits food intake by activation of the
CCKA receptor subtype (58, 59). Antagonists of CCKA
receptor signaling increase meal size in monkeys (60). One
animal model of obesity, the Otsuka Long-Evans
Tokushima fatty rat, exhibits increased energy intake and
has a defect in the CCKA receptor (61). However, other
genes appear to be involved in the pathophysiology of obe-
sity and diabetes in this animal model (62). In addition,
these rats have defects in CCK-induced insulin secretion,
which could also contribute to their obese phenotype (63).
CCK is likely to transmit vagal afferent signals to the hind-
brain by acting on receptors located in the pylorus and
liver. Because CCK is also a potent inhibitor of gastric
emptying (65, 65), some of its effects to limit food intake
may be indirectly mediated by the retention of food in the
stomach.
CCK is also produced in the CNS, is localized in sev-
eral brain areas involved in food intake regulation (reviewed
in Ref. 66), and is released from hypothalamic neurons dur-
ing feeding (67, 68). Administration of CCK into the cere-
bral ventricles inhibits food intake in nonhuman primates
(69) at doses that are ineffective when given peripherally
(70). CCKA receptor-specific agonists reduce food intake
(71), suggesting that the central effects of CCK also involve
CCKA receptors.
Although CCK reduces meal size, long-term peripheral
administration of CCK does not reduce overall energy in-
take or induce sustained weight loss (72). In a study con-
ducted by West and Woods (73), repeated administration of
CCK when meals were initiated decreased meal size in rats;
however, the number of meals eaten increased and after an
initial period of adaptation, overall energy intake was un-
affected and weight loss was minimal. Thus, although CCK
functions as a short-term signal to inhibit food intake by
inducing satiety and decreasing meal size, over time these
short-term actions appear to be compensated for by reduced
input from long-term regulators of energy balance (e.g.,
insulin and leptin), which decrease as a consequence of the
CCK-induced reduction of energy intake.
GLP-1. GLP-1 is secreted by the endocrine L cells in
the ileum (74) in response to the entry of nutrients into the
small intestine. The GLP-1 response to food ingestion may
be at least partially mediated via parasympathetic vagal ac-
tivation (75); however, inhibition of GLP-1 by cholinergic
blockade may also be a result of reduced GI motility. GLP-
1, along with GIP, can contribute to nutrient-induced insulin
secretion (76), and it is therefore considered to be an ‘in-
cretin’ hor mone. Intravenous administration of GLP-1 has
satiating actions in humans (77, 78), with inhibition of gas-
tric emptying (78, 79) being a likely contributor to this
effect. However, GLP-1 could also inhibit food intake by
binding to GLP-1 receptors on afferent nerves in the liver
and/or GI tract and activating vagal afferent nerves to the
CNS. Intraventricular administration of GLP-1 inhibits food
intake (80, 81), and central administration of GLP-1 antago-
nists increases feeding in rodents (80, 82), suggesting a role
for endogenous GLP-1 in the regulation of food intake.
However, since GLP-1 is produced in both the periphery
and in hypothalamic neurons, the extent to which GLP-1
from each of these sources participates in the physiological
regulation of feeding behavior is unclear.
Gastrin-releasing polypeptide (GRP)/bombesin.
GRP, a peptide produced by endocrine cells in the gastric
mucosa, is the mammalian homologue of a peptide (bombe-
sin) first isolated from glands in the skin of amphibians
(reviewed in Ref. 83). GRP not only regulates secretion of
gastrin, but its peripheral administration (and that of bombe-
sin) inhibits food intake in animals (84), and its intravenous
infusion reduces appetite and food intake in humans (85).
Because GRP/bombesin also potently delays gastric emp-
tying (86), the extent to which these effects on GI motility
contribute to the reduction of food intake is uncertain. How-
ever, intracerebroventricular injection of bombesin at a dose
that has no peripheral effects decreases the size of meals in
free-feeding baboons (87), suggesting that GRP-related
peptides have a role in the central regulation of food intake.
Ghrelin. Ghrelin, a recently discovered peptide hor-
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mone that is structurally related to motilin, is produced by
the stomach (88). It was first identified based on its stimu-
lation of growth hormone secretion via a growth hormone
secretagogue receptor in animals and humans (reviewed in
Refs. 89 and 90), Ghrelin is also produced in the hypothala-
mus (91). Circulating ghrelin concentrations increase during
fasting (92), are reduced by the presence of nutrients in the
stomach (92), and are lower in obese versus lean human
subjects (93). In contrast to the anorexigenic effects of other
GI peptide hormones, peripheral or central administration of
ghrelin increases food intake in rodents, whereas adminis-
tration of antibodies against ghrelin inhibits feeding (92, 94,
95). Central ghrelin administration also increases hypotha-
lamic expression of the NPY (95). Daily peripheral ghrelin
administration induces a progressive increase in body
weight in rats that could result from a chronic decrease of
fat oxidation as indicated by an increased respiratory quo-
tient (92). Because ghrelin-induced increases of adiposity
appear to be sustained over 1 week of treatment, there is
potential for ghrelin to have a role in long-term body weight
regulation.
Other GI peptides. In addition to those discussed
above, a large number of other peptides produced by the
stomach, intestine, and endocrine pancreas inhibit food in-
take (reviewed in Refs. 96 and 97). Glucagon and pancreatic
polypeptide are secreted during food ingestion from pancre-
atic islet endocrine A and F cells, respectively (98). Al-
though peripheral or central administration of glucagon (99,
100) or peripheral administration of pancreatic polypeptide
(101) can inhibit feeding in rodents, a physiological role for
these pancreatic hormones in food intake regulation has not
been established. Enterostatin, a pentapeptide that results
from trypsin-induced cleavage of procolipase, is produced
in response to dietary fat and appears to selectively inhibit
fat intake. Chronic administration of enterostatin produces
weight loss in animals (reviewed in Refs. 102 and 103).
Central or peripheral administration of somatostatin reduces
food intake in animals (104) and produces satiety in humans
(105). Amylin, which is cosecreted with insulin from pan-
creatic  cells and a related peptide, calcitonin gene-related
peptide, inhibit food intake after peripheral administration
in rats (106, 107). Gastric inhibitory polypeptide, also
known as glucose-dependent insulinotropic polypeptide
(GIP), is secreted from intestinal endocrine K cells after
glucose administration or ingestion of high carbohydrate
meals (76). Administration of a somatostatin analog, octreo-
tide, in order to inhibit GIP and GLP-1 secretion prevents
the subsequent decrease of food intake and increase of hun-
ger ratings normally seen after intraduodenal administration
of carbohydrate in humans (108). However, since somato-
statin itself has effects on gastric emptying and food intake
the extent to which decreased GIP and GLP-1 secretion
mediate these effects is uncertain.
In summary, although many GI peptide hormones can
potently inhibit food intake, their physiological role in food
intake regulation, with the exception of CCK and possibly
ghrelin, has yet to be definitively established.
Other Endocrine Regulators of Food Intake and
Energy Balance
Cytokines. Peripheral or central administration of a
number of cytokines, including IL-6 and TNF-, inhibit
food intake (reviewed in Ref. 109). Although cytokines are
certainly involved in the anorexia associated with infection
and cancer (110, 111), their role in regulating food intake
under physiological conditions (i.e., in the absence of neo-
plasia or inflammation) is not well understood. Cytokines
may also influence food intake indirectly via actions on
insulin sensitivity (112) or leptin production (113, 114).
Glucocorticoids. Although glucocorticoids are pri-
marily catabolic in the periphery, they have anabolic effects
in the CNS (reviewed in Ref. 115) where they act to in-
crease food intake (116). The changes in hypothalamic neu-
ropeptide systems that inhibit food intake in response to
insulin and leptin are for the most part opposed by gluco-
corticoids, and this is likely to mediate their central orexi-
genic effects (reviewed in Ref. 117). Glucocorticoid defi-
ciency (Addison’s Disease) is associated with anorexia. Al-
though glucocorticoid administration and endogenous
overproduction of glucocorticoids (Cushing’s syndrome)
are associated with hyperphagia (118), the concurrent hy-
perinsulinemia and hyperleptinemia (119), as well as the
peripheral catabolic actions of glucocorticoids, are likely to
prevent overt obesity in most Cushing’s patients. Glucocor-
ticoids probably interact with insulin and leptin in the long-
term regulation of energy intake and body adiposity. For
example, adrenalectomy increases sensitivity to the effect of
central insulin administration to reduce food intake (120),
whereas chronic glucocorticoid administration appears to
impair CNS insulin transport (121). Hyperphagia in animals
with leptin deficiency or leptin receptor defects is attenuated
by adrenalectomy (reviewed in Ref. 122), suggesting im-
portant interactions between the effects of leptin deficiency/
resistance and the hypothalamic-pituitary-adrenal axis.
Thyroid Hormones. The mechanisms by which thy-
roid hormones influence feeding behavior are not well un-
derstood. Food intake is increased by thyroid administration
or endogenous hyperthyroidism; however the increase is
likely to be mediated by thyroid hormone perturbations of
energy expenditure. That is, thyroid hormones induce a
marked stimulation of basal metabolic rate, creating a state
of negative energy balance associated with loss of body fat
and reduced circulating leptin and insulin, which would lead
to increased energy intake. In contrast, hypothyroidism de-
creases basal metabolic rate and leads to weight gain and
reduced food intake. Nonetheless, hypothyroidism does not
cause marked obesity, perhaps because weight gain is lim-
ited by increased insulin and leptin. In addition, the removal
of feedback inhibition of hypothalamic thyrotropin-
releasing hormone by the reduced levels of thyroxine oc-
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curring in hypothyroidism could limit weight gain because
central administration of thyrotropin-releasing hormone
suppresses food intake (123).
Growth Hormone/IGF Axis. The hypothalamic
growth hormone-insulin-like growth factor (IGF) axis has
important effects on energy balance and nutrient partition-
ing. Administration of exogenous growth hormone is asso-
ciated with increased food intake, and central administration
of IGF-I, but not IGF-II, inhibits feeding (124). The extent
to which this effect is mediated by binding to insulin recep-
tors is unclear. Both growth hormone and IGFs can exert
negative feedback inhibition on the somatotrophic axis via
growth hormone releasing hormone (GHRH) in the hypo-
thalamus. Since intraventricular administration of GHRH
agonists (125) or injection of GHRH into the hypothalamic
ventromedial nucleus (126) increases food intake in rats, it
is possible that peripheral growth hormone and IGF could
modulate feeding behavior through hypothalamic GHRH.
Long-Term Regulation of Food Intake and
Energy Balance
Insulin. It was first proposed by Woods and col-
leagues (127) in the early 1970s that insulin is a long-term
regulator of food intake, energy balance, and body adipos-
ity. Since that time, much additional evidence has been
generated in support of this hypothesis (128, 129). Insulin
secretion from islet  cells of the endocrine pancreas is
stimulated by food ingestion. This is a coordinated effect
mediated via activation of the parasympathetic nerves in-
nervating the pancreas, the direct effect of incoming nutri-
ents, specifically glucose and amino acids, and the stimu-
lation by incretin hormones such as GIP and GLP-1 (76).
Figure 2. Long-term signals regulating
food intake and energy homeostasis. In-
sulin and leptin are the two most impor-
tant long-term regulators of food intake
and energy balance. Both insulin and
leptin act in the CNS to inhibit food intake
and to increase energy expenditure,
most likely by activating the sympathetic
nervous system (SNS). Insulin is se-
creted from  cells in the endocrine pan-
creas in response to circulating nutrients
(glucose and amino acids) and to the in-
cretin hormones, glucose-dependent in-
sulinotropic polypeptide (GIP) and GLP-
1, which are released during meal inges-
tion and absorption. Insulin can also act
indirectly by stimulating leptin production
from adipose tissue via increased glu-
cose metabolism. In contrast, dietary fat
and fructose do not stimulate insulin se-
cretion and therefore do not increase lep-
tin production. There is also evidence
that leptin can inhibit insulin secretion
from the pancreas. The gastric hormone
ghrelin increases food intake and de-
creases fat oxidation in rodents and may
have an anabolic role in long-term food
intake regulation. The long-term signals
interact with the short-term signals in the
regulation of energy homeostasis and
appear to set sensitivity to the satiety-
producing effects of short-term signal
such as CCK.
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Both fasting plasma insulin levels and insulin responses to
meal ingestion are correlated with body adiposity. Accord-
ingly, over a 24-hr period, overall insulin secretion and the
concentrations of insulin in the systemic circulation are pro-
portional to both body fat content and to recent carbohy-
drate and protein intake (44). Dietary fat does not stimulate
insulin secretion (44), although the presence of some fatty
acids appears to be necessary for the full insulin secretory
response to glucose (130).
Insulin receptors have been identified in a number of
brain regions implicated in the regulation of feeding behav-
ior, including the arcuate nucleus of the hypothalamus (re-
viewed in Ref. 131). Although CNS neurons do not produce
insulin, this hormone is transported into the brain by a re-
ceptor-mediated mechanism that is saturated at high insulin
concentrations (132). Insulin transport into the CNS is not
rapid, occurring over a period of hours after circulating
insulin concentrations increase, consistent with a role for
insulin in the long-term regulation of body adiposity rather
than as a short-term satiety signal. In 1979, Woods, Porte
and colleagues (123) reported that continuous infusion of
insulin into the cerebral ventricles of free-feeding baboons
induced a sustained suppression of food intake over a period
of 20 days. This inhibition of food intake was accompanied
by progressive reduction of body weight.
Insulin’s effects to decrease food intake involve inter-
actions with several hypothalamic neuropeptides that are
also involved in the regulation of feeding behavior by leptin,
including the NPY and melanocortin ligands and their re-
ceptors (134, 135). In an experiment designed to examine
the role of insulin in the brain in the presence of insulin
deficiency, insulin was infused into the cerebral ventricles
of insulin-deficient diabetic rats at a rate low enough so that
circulating insulin or glucose levels were unaffected. The
marked increase of food intake known as diabetic hyper-
phagia was reduced by 50% by insulin infusion, indicating
that central insulin deficiency contributed to, but was not
solely responsible for, the hyperphagia in this model of
diabetes (136). The importance of central insulin signaling
in regulating energy balance was reinforced by the recent
report that mice with a neuron-specific genetic knockout of
the insulin receptor exhibit increased food intake and have
larger adipose stores (137). In addition to inhibiting food
intake, insulin increases sympathetic neural activity and en-
ergy expenditure (138, 139). Thus, insulin can modulate
energy balance by inhibiting energy intake and by increas-
ing thermogenesis. An important interaction of insulin as a
long-term signal in regulating energy balance with the
short-term satiety signal CCK has been demonstrated. Ad-
ministration of insulin into the CNS of baboons at a dose
that by itself did not significantly decrease food intake al-
lowed a subthreshold dose of either intravenous or intraven-
tricular CCK to inhibit feeding (140, 141). In these studies,
energy intake decreased by more than 50% with the com-
bination of insulin plus CCK, suggesting that sensitivity to
the effect of CCK to induce satiety is enhanced by insulin’s
action in the brain.
As reviewed above, there is considerable evidence sup-
porting the view that insulin signaling in the brain limits
food intake and that over the long term, insulin secretion
functions as a negative feedback signal of recent energy
intake and body adiposity. However, because insulin also
has peripheral anabolic effects that increase lipid synthesis
and storage, a misconception that insulin causes weight gain
and obesity has evolved. The idea that insulin promotes
obesity has led to the promulgation of a number of popular
diets that propose to induce weight loss by avoidance of
foods that stimulate insulin secretion. These assertions fail
to differentiate between insulin responses to meals in which
circulating insulin concentrations rapidly rise and then re-
turn to basal levels within a short period of time and the
chronic hyperinsulinemia that results from  cell compen-
sation for insulin resistance. In fact, in human subjects,
increased insulin secretion in response to glucose is predic-
tive of a smaller degree of subsequent weight gain, rather
than a factor leading to greater weight gain and obesity
(142). In addition, after feeding, insulin is preferentially
transported into the hypothalamus compared with other
brain areas, and hypothalamic insulin content is increased
after high carbohydrate meals, but not after high fat meals
(143). This is likely due to the much smaller circulating
insulin responses when high fat meals are consumed (44).
Lastly, chronic consumption of a high fat diet in dogs im-
pairs brain insulin transport, and the impairment is predic-
tive of weight gain in response to the high fat feeding (144).
Together, these effects of reduced insulin secretion and re-
duced insulin transport into the CNS could contribute to the
increased energy intake and obesity observed in animals and
humans consuming high fat diets (39–42).
Leptin. History of leptin. In 1953, Kennedy (145)
proposed that body weight is regulated over a prolonged
period of time by a humoral factor produced by adipocytes
in proportion to the amount of lipid stored in adipose tissue.
The elegant parabiosis experiments conducted by Coleman
and coworkers indicated that the genetically obese ob/ob
mouse failed to produce a factor that inhibits food intake. In
contrast, the similarly obese db/db mouse appeared to pro-
duce such a substance, but did not respond with decreased
food intake (146, 147). In a study designed to identify fac-
tors produced by adipose tissue from chronically overfed
macaques, Wilson and colleagues (148) utilized subtraction
cloning to identify cDNA segments coding for overex-
pressed RNA transcripts. Although a cDNA sequence cod-
ing for a transcript with enhanced expression was found, the
protein was not identified by this experiment. Leptin was
discovered in 1994, when the gene responsible for obesity in
the ob/ob mouse was positionally cloned (149). This gene is
expressed primarily in adipose tissue and codes for a 16-
kDa protein now known as leptin. Soon after the leptin
receptor gene was cloned in 1995 (150), mutations in this
gene were identified in genetically obese db/db mice and
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fa/fa rats (151, 152). There are several subtypes of the leptin
receptor, with the long form (OB-Rb), which utilizes the
JAK-STAT signal transduction pathway, appearing to be
essential for leptin’s central inhibition of food intake (re-
viewed in Ref. 153).
Leptin action and role in human energy balance.
Administration of leptin acutely decreases food intake and
induces weight loss in rodents (reviewed in Refs. 154 and
155). Leptin has also been implicated in the regulation of
energy expenditure since its administration induces greater
weight loss than can be explained solely by the reduction of
food intake (156, 157). This enhanced energy expenditure is
mediated via activation of the sympathetic nervous system
(158, 159). Central administration of leptin into the third
ventricle of rhesus monkeys increases circulating levels of
the sympathetic neurotransmitter, norepinephrine, within 30
min, and produces a slower onset reduction of food intake
that is sustained over more than 24 hr (160).
Humans with mutations causing complete leptin defi-
ciency (161, 162) or with defects in the leptin receptor (163)
exhibit marked hyperphagia and severe obesity. Small doses
of leptin reduce hyperphagia and cause weight loss com-
prised exclusively of body fat in leptin-deficient patients
(164), whereas administration of leptin to humans without
leptin deficiency induces only modest and variable weight
loss (165, 166). The observation that leptin levels are el-
evated in the vast majority of obese individuals has led to
the hypothesis that most obese subjects are resistant to the
actions of leptin (154). Leptin resistance could result from
decreased leptin transport into the CNS (167, 168) or to
impaired signaling downstream of the leptin receptor (169,
170). Together, these observations are consistent with the
hypothesis that the biological impact of leptin is more pro-
nounced when leptin levels are decreasing than when cir-
culating leptin concentrations are elevated. Supporting this
view is the observation that when endogenous leptin levels
were chronically decreased in women during prolonged
consumption of a moderately energy-restricted diet, their
increased sensations of hunger correlated with reduction of
plasma leptin levels (171). These results suggest a role for
leptin in the regulation of appetite in humans when leptin
production is decreased.
An important interaction between leptin as a long-term
regulator of energy balance and the short-term satiety signal
CCK has recently been demonstrated (172). In this experi-
ment, a dose of peripheral CCK that reduced short-term
food intake by more than 50% in fed rats was ineffective at
reducing meal size in rats in which circulating leptin levels
were reduced by fasting for 48 hr. However, when the fall
of leptin in fasted rats was prevented by administering leptin
at a low rate in order to match leptin levels in the ad libitum-
fed animals, the ability of CCK to decrease food intake in
these fasted animals was restored. Synergistic actions of leptin
and CCK on food intake have been shown in several other
studies (173–177), providing evidence for integration of
long-term and short-term signals regulating energy balance.
Regulation of leptin production. Circulating leptin
concentrations are highly correlated with indices of body fat
content in humans (178–180) and in animals (178, 181,
182). There is a gender difference in circulating leptin lev-
els, with 3- to 4-fold higher concentrations in women than
in men with a comparable body mass index (183, 184). This
difference persists after correction for greater body adipos-
ity in women and does not appear to be explained by an
effect of female reproductive hormones; i.e., plasma leptin
concentrations do not differ between pre- and postmeno-
pausal women, and hormone replacement therapy does not
alter the relationship between leptin and body adiposity
(184). It is possible that the gender difference results from
inhibition by androgens and/or differences in body fat dis-
tribution between men and women.
Despite the close correlation between circulating leptin
concentrations and body adiposity, plasma leptin levels de-
crease independently of modest changes of body fat content
during short-term periods of fasting (185, 186) or during
restriction of energy intake (171, 187), and they increase
after refeeding (186, 188) or during overfeeding (189).
These acute, adiposity-independent decreases of leptin pro-
duction in response to an energy deficit would be expected
to promote increased energy intake and energy conservation
before body fat stores become significantly depleted. A
number of studies have demonstrated that insulin and glu-
cose can modulate leptin secretion. Insulin increases leptin
gene expression and leptin secretion in vitro and in vivo
(reviewed in Ref. 155). For example, glucose infusion in-
creases plasma leptin levels in rhesus monkeys (190), and
infusion of insulin at rates producing supraphysiological
(191) or physiological (192) insulin levels increases circu-
lating leptin concentrations in humans after several hours of
infusion. The decrease of plasma leptin during fasting in
humans is prevented by infusing glucose at a low rate suf-
ficient to prevent decreases of plasma glucose and insulin.
(185). Several studies have shown that the reduced circu-
lating leptin levels observed in response to energy restric-
tion are well correlated with decreases of plasma glucose
(171, 187, 193). Circulating leptin levels decline quickly
after the onset of hyperglycemia when insulin-deficient dia-
betes is induced in rodents with the  cell toxin streptozoto-
cin; also, leptin levels are restored with insulin treatment
that normalizes plasma glucose (194, 195). Interestingly,
when the fall of leptin in diabetic rats is prevented by in-
fusing leptin at a low rate via a chronically implanted os-
motic minipump, the hyperphagia characteristic of un-
treated insulin-deficient diabetes does not develop (196).
These results indicate that low leptin levels make an impor-
tant contribution to diabetic hyperphagia. In another study,
preventing the decrease of leptin during fasting in rats im-
paired the induction of the dopamine receptor-mediated
food-seeking behavior known as conditioned place prefer-
ence, providing further evidence that decreased leptin has a
significant biological impact on feeding behavior (197).
The mechanisms by which insulin and glucose regulate
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leptin production by adipose tissue are the focus of consid-
erable research. A series of in vitro studies conducted in
isolated adipocytes demonstrated that when glucose trans-
port or glycolysis is blocked, insulin-stimulated activation
of leptin gene expression and leptin secretion are inhibited
in proportion to the impairment of glucose utilization (198).
This inhibition of leptin expression and secretion occurs
despite the presence of insulin in the culture media at con-
centrations at the high end of the physiological range (198),
demonstrating that insulin-mediated glucose metabolism,
and not insulin per se, stimulates leptin production. Further-
more, insulin-induced activation of the transcriptional ac-
tivity of the leptin promoter is blocked by inhibition of
glucose utilization (199). Other experiments have shown
that anaerobic metabolism of glucose to lactate does not
stimulate leptin secretion (200) and suggest that glucose
must be aerobically metabolized to CO2 in the mitochondria
in order to increase the production of leptin by adipose
tissue (201). These results indicate that adipocyte glucose
utilization is an important determinant of insulin-mediated
leptin gene transcription, mRNA expression, and leptin pro-
tein secretion. The effects of energy restriction and refeed-
ing to respectively decrease and increase circulating leptin
concentrations independent of adiposity are likely to be a
consequence of altered oxidative glucose metabolism in adi-
pose tissue, resulting from fluctuations of insulin secretion
and glycemia.
Circulating leptin concentrations exhibit a diurnal pat-
tern with a pronounced nocturnal peak (202). This diurnal
pattern is not observed if the subjects do not eat (185, 192),
and in fact, leptin concentrations fall and remain low until
4–6 hr after a meal is consumed (44). The timing of the
nocturnal peak is dependent on when meals are eaten (203).
Accordingly, the diurnal leptin pattern is not a true circadian
rhythm, unlike the diurnal patterns of cortisol and growth
hormone secretion. Although administration of high doses
of exogenous glucocorticoids can increase circulating leptin
concentrations (204, 205), a major role for endogenous glu-
cocorticoids as positive regulators of leptin production does
not appear likely. Glucocorticoid levels increase during en-
ergy restriction and in unregulated diabetes when circulat-
ing leptin concentrations are markedly reduced (187, 195).
Furthermore, the 24-hr leptin pattern is still present in sub-
jects with an absent 24-hr cortisol rhythm due to adrenal
insufficiency and it is unaffected by cortisol infusions de-
signed to mimic or reverse the timing of the normal circa-
dian cortisol rhythm (206). Nonetheless, it is possible that
cortisol and growth hormone can modulate the diurnal lep-
tin pattern via their effects on insulin sensitivity (207, 208).
However, the most important determinant of the both the
diurnal leptin pattern and the influence of energy intake on
circulating leptin concentrations in humans appears to be
the effect of insulin to stimulate glucose metabolism in adi-
pose tissue (155, 209).
If insulin and adipocyte glucose metabolism regulate
leptin production in vivo, then it would be reasonable to
propose that consumption of high fat meals that induce less
insulin secretion and smaller glucose excursions would lead
to lower leptin production and reduced circulating leptin
concentrations. In several early studies that examined only
morning fasting leptin concentrations, no effect of dietary
fat content was observed (180, 186). However, in a study
examining circulating leptin concentrations over a 24-hr pe-
riod, consumption of high fat meals resulted in significant
reductions in leptin levels, with the largest occurring 4–6 hr
after each meal when compared with the same subjects con-
suming high carbohydrate meals (44). Since both the am-
plitude of the nocturnal peak of leptin and overall leptin
production are significantly reduced by consumption of
high fat meals, this decrease, along with reduced insulin
secretion, could contribute to the well-known effects of high
fat diets to promote increased energy intake, weight gain,
and obesity in humans and animals (39–42).
Although glucose infusion or ingestion of carbohydrate
meals with high glucose content enhance insulin secretion
and consequently leptin production, another major source of
dietary carbohydrate, fructose, does not directly stimulate
insulin secretion from pancreatic  cells (210). Accord-
ingly, intravenous infusion of fructose does not increase
insulin secretion or circulating leptin concentrations in rhe-
sus monkeys, whereas leptin levels increase progressively
during infusion of a comparable amount of glucose (190). In
human subjects, insulin responses were reduced and over a
24-hr period, circulating leptin levels were lower when a
fructose-sweetened, rather than an isocaloric glucose-
sweetened, beverage was consumed with each meal (211).
Because insulin and leptin function as long-term regulators
of energy balance, consumption of diets with a high per-
centage of energy derived from fructose could lead to in-
creased energy intake and obesity (212).
Other Adipocyte Factors Involved in the
Regulation of Energy Balance and Insulin Action
In addition to leptin, a number of other factors secreted
by adipocytes or that regulate adipocyte metabolism have
been implicated in the regulation of energy balance. For
example, acylation stimulating protein (ASP), which is pro-
duced by adipocytes as a result of interaction of comple-
ment factor C3, factor B, and adipsin, has a role in increas-
ing the efficiency of triacylglycerol synthesis (reviewed in
Refs. 213 and 214). Mice that lack the ability to synthesize
ASP have delayed postprandial lipid clearance (215). How-
ever, ASP deficiency also has a major impact on energy
balance and insulin action. Despite increased energy intake,
C3/ASP knockout mice have significantly reduced adipose
tissue depots compared with wild-type animals fed either
chow or high fat diet, indicating that these animals have
elevated energy expenditure (216). In addition, the knock-
out animals have reduced fasting insulin levels and im-
proved glucose tolerance (215, 216). Interestingly, mice
with a knockout of another protein involved in triacylglyc-
erol synthesis, the enzyme diacylglycerol acyltransferase,
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are also lean and resistant to diet-induced obesity (217).
Enhancement of adipocyte lipolysis can have a similar ef-
fect on energy balance. This is indicated by the finding that
mice with a knockout of the gene for perilipin and hence an
elevated activity of hormone-sensitive lipase are hyperpha-
gic and lean with smaller adipocytes and that the absence of
perilipin reverses obesity even in leptin receptor-deficient
db/db mice (218, 219).
Another adipocyte protein that is of considerable inter-
est with regard to the regulation of energy balance and
insulin action is adiponectin (220, 221), which is also
known as gACRP30, a cleavage product of adipocyte
complement-related protein 30 (222), and as adipoQ (223).
Circulating adiponectin levels are reduced in obese humans
(221) and rhesus monkeys (224). In humans, adiponectin
levels are negatively correlated with fasting insulin concen-
trations and positively correlated with insulin sensitivity
(225), and the decline of adiponectin in rhesus monkeys
coincides with the onset of insulin resistance (224). Admin-
istration of adiponectin/gACRP30 induces weight loss in
mice consuming a high fat, high sucrose diet without de-
creasing food intake, an effect that is associated with in-
creased fatty acid oxidation in muscle (226). Fatty acid
oxidation is also increased and associated with a lean phe-
notype in acetyl-coenzyme A carboxylase 2 knockout mice
(227). Interfering with adipocyte development appears to
have a similar effect, as shown by the observation that mice
lacking a protein involved in adipogenesis, Hmgic, are re-
sistant to diet-induced obesity, and the absence of Hmgic
reduces obesity in leptin-deficient (ob/ob) mice (228). An-
other novel adipocyte factor, resistin, is reported to be
downregulated by PPAR and increased in obese, insulin-
resistant animals and therefore has been implicated in the
insulin resistance of obesity (229). However, a recently pub-
lished study has reported that resistin expression is de-
creased in several obese rodent models and increased by
insulin-sensitizing PPAR agonists (230), bringing into
question the hypothesis that insulin resistance in obesity is
mediated by resistin.
Summary
Short-term signals are primarily from the GI tract (e.g.,
CCK and GI stretch receptors) and are involved in promot-
ing sensations of satiety that lead to meal termination. These
short-term signals by themselves are not sufficient to regu-
late energy balance and body adiposity. The long-term sig-
nals insulin and leptin are produced and circulate in pro-
portion to recent energy intake and body adiposity. To-
gether, the short- and long-term signals interact to regulate
energy balance in that insulin and leptin appear to determine
the sensitivity of the brain to the satiety-producing effects of
the short-term signals from the GI tract. In addition to the
critical role of leptin in regulating food intake and energy
expenditure, a number of other adipocyte hormones and
proteins have recently been implicated in the regulation of
energy balance and insulin action.
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